Fortunately, this post of mine from September aged poorly, as I believe as many as 11 deals have already been closed since then! Nice progress, which in my opinion isn’t yet fully reflected in the stock’s valuation.
6 Likes
Now NG has tapped into a goldmine. If this launch takes off, they won’t need anything else. Aging and the beauty business are areas where money seems to lose all meaning when people are chasing eternal youth. Fantastic move!
11 Likes
This wasn’t the first deal in this sector. If I recall correctly, a similar one came through for the US in the fall. So the direction is damn good!
8 Likes
Now!
11 Likes
Permit, expected that we’d get it. The essential thing is business growth, now we get to start.
1 Like
It is important to note that, according to the release, approval has currently only been granted for certain individual blood biomarkers. According to the company’s website, the measurement currently includes around 250+ blood biomarkers, so we will still have to wait before the entire product can be sold in New York.
Quote from the press release:
…the laboratory must first obtain a clinical laboratory permit, after which the laboratory must submit validation data for each of its LDT tests, i.e., individual blood biomarkers included in the Nightingale Health Check service, for review by CLEP. The approvals now obtained are the first for Nightingale Health’s tests…
EDIT: fixed the broken formatting in the quote
3 Likes